Adult research
Psychedelics research
Scientific evidence on psychedelic research: methods, findings, limitations and public health.
Psychedelics research spans laboratory mechanisms, human pharmacology and clinical trials. Findings depend on the compound, population, comparator and follow-up; a promising result is neither universal benefit nor proof of safety.
A clinical trial is designed to answer a research question, while routine care addresses individual clinical needs. Registration and oversight do not promise benefit or turn an investigational intervention into established care.
A psilocybin trial evaluates a defined investigational product in a defined study. Its results do not establish equivalent effects or safety for different formulations or mushroom material.
Psychedelic is sometimes a broad research label that includes classical psychedelics and MDMA. Shared terminology does not make their pharmacology, clinical findings or risks interchangeable.
Psilocybin is converted in the body to psilocin, its active metabolite. Measuring that molecule helps explain acute pharmacology; it does not predict clinical recovery or an individual outcome.
Research summaries explain evidence and uncertainty. They are not medical advice or instructions for use.